Study Evaluating LXR-623 in Healthy Subjects

Wyeth

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: LXR-623

Study type: Interventional

Funder types: Industry

Identifiers

NCT00366522

3201A1-100

Details and patient eligibility

About

To evaluate the safety and tolerability of a single dose of LXR-623 in healthy subjects.

Sex: All

Ages: 19 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion:

• Healthy, men or women, aged 19-50 years

Exlcusion:

• Use of any investigational or prescription drug within 30 days before study start
• Any clinically imprtant medical disease or abnormal laboratory test results

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind